{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:47:21Z","timestamp":1776793641365,"version":"3.51.2"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2022.01.020","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:18:53Z","timestamp":1643739533000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["In vitro activity of imipenem\/releactam and comparator agents against clinical bacterial isolates from patients with cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Kenneth V.I.","family":"Rolston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahgat Z.","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Reitzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A.","family":"Shelburne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel L.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam I.","family":"Raad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall A.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.01.020_bib0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.020_bib0002","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","article-title":"Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance","volume":"32","author":"Montassier","year":"2013","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.jgar.2022.01.020_bib0003","first-page":"P0673","article-title":"Bloodstream infection survey in high-risk oncology patients (BISHOP) with fever and neutropenia (FN): microbiology data","author":"Rolston","year":"2018","journal-title":"ESCMID"},{"key":"10.1016\/j.jgar.2022.01.020_bib0004","first-page":"2819","article-title":"The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC \u201cNeutropenia, Infection and Myelosuppression\u201d Study Group during the MASCC annual meeting held in Berlin on 27\u201329 June 2013","volume":"24","author":"Rapoport","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgar.2022.01.020_bib0005","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1469-0691.2012.03879.x","article-title":"Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients","volume":"19","author":"Gudiol","year":"2013","journal-title":"Clin Microbiol Infec"},{"key":"10.1016\/j.jgar.2022.01.020_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America\u2019s 10 \u00d7 \u201920 initiative (ten new systemic antibacterial agents FDA-approved by 2020): is 20 \u00d7 \u201920 a possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.020_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2022.01.020_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00997-19","article-title":"In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa","volume":"63","author":"Asempa","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.01.020_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.01.020_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","article-title":"In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015\u20132017","volume":"21","author":"Karlowsky","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2022.01.020_bib0011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1099\/jmm.0.001142","article-title":"In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015\u20132017","volume":"69","author":"Lob","year":"2020","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2022.01.020_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.01.020_bib0013","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10096-019-03553-8","article-title":"In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015\u20132016","volume":"38","author":"Galani","year":"2019","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.jgar.2022.01.020_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing, 29th ed M100","year":"2019"},{"key":"10.1016\/j.jgar.2022.01.020_bib0015","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/ofid\/ofz004","article-title":"Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: analysis of the distribution of beta-lactamase resistance genes and lineage background in the United States","volume":"6","author":"Mendes","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.01.020_bib0016","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jgar.2022.01.020_bib0017","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgar.2022.01.020_bib0018","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:02:57Z","timestamp":1761991377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":18,"alternative-id":["S2213716522000261"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.01.020","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of imipenem\/releactam and comparator agents against clinical bacterial isolates from patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}